Helen McShane

helen mcshane

Professor of Vaccinology

Jenner Institute, University of Oxford, UK

Tel: +44 (0)1865 617606

Email: Helen.McShane@ndm.ox.ac.uk





Network Director, Network Management Board Member, Management Team Member, Network Investigator


Research Keywords: 

Immunology & Infectious Diseases; Tuberculosis; HIV; Vaccines;  Human Challenge Models; Preclinical Animal Models



Helen McShane is VALIDATE Network Director and the Director of the Oxford NIHR Biomedical Research Centre; Professor of Vaccinology at Oxford University; Deputy Head (Translation and Personnel), Medical Sciences Division; and an Honorary Consultant Physician in infectious diseases.  

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award. Helen was elected to be a fellow of the Academy of Medical Sciences in 2019. 

Since 2001, Helen has led a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials.

Most recently, Helen has been leading the coordination of COVID-19 drug trials within Oxford and nationally and is now leading a programme to establish a controlled human infection model with SARS CoV2 which will allow the evaluation of protective immunity.


Related Websites: 

Profile page at The Jenner Institute



Key Publications:

Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; for the MVA85A 030 trial investigators. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015 Feb 25. pii: S2213-2600(15)00037-5. [Epub ahead of print] PMID: 25726088

Satti I, Meyer J, Harris SA, Thomas ZR, Griffiths K, Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, Bettinson H, McShane H.  Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014 14(10), 939–946. PMID: 25151225

Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23; 381(9871):1021-8. PMID: 23391465

Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Moyo S, Brittain N, Lawrie A, Mulenga H, de Kock M, Makhethe L, Esme Janse van Rensburg, Gelderbloem S, Veldsman A, Hatherill M, Geldenhuys H, Hill AVS, Hawkridge A, Hussey GD, Hanekom WA, McShane H and Mahomed H. A phase IIa trial of the new TB vaccine, MVA85A, in HIV and/or M. tuberculosis infected adults. Am J Respir Crit Care Med. 2012 Apr 1; 185(7):769-78. PMID: 22281831

Minassian AM, Rowland R, Beveridge NER, Poulton ID, Satti I, Harris S, Poyntz H, Hamill M, Griffiths K, Sander CR, Ambrozak DR, David A Price DA, Casazza JP, Daniel C Douek DC, Koup RA, Roederer M, Winston A, Jonathan Ross J, Sherrard J, Rooney G, Alder N, Lawrie AM, Fletcher HA, Pathan AA and McShane H. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open. 2011 Nov 14; 1(2) PMID: 22102640

Ota, MOC, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, Williams N, Rowland-Jones S, Hill AVS, Adegbola RA and McShane H. Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants. Sci Transl Med 22 June 2011: Vol. 3, Issue 88, p. 88ra56 PMID: 21697532

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010 Jan; 40(1):279-90. PMID: 20017188

Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H. Safety and Immunogenicity of a New TB Vaccine, MVA85A, in M. tuberculosis Infected Individuals. Am J Respir Crit Care Med. 2009 Apr 15; 179(8):724-33. PMID: 19151191

Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, Hill AVS, Adegbola R, McShane H. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis endemic countries: issues in study design. The Lancet Infectious Diseases 2006; 6:522-28. PMID: 16870530

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AVSH. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans. Nature Medicine 2004. 10(11):1240-4. PMID: 15502839